High prevalence of lower extremity peripheral artery disease in type 2 diabetes patients with proliferative diabetic retinopathy.

PLoS One

Department of Endocrinology, Beijing Tongren Hospital, Capital Medical University, Beijing, China; Beijing Key Laboratory of Diabetes Research and Care, Beijing, China.

Published: March 2016

Little is known about the relationship between lower extremity peripheral arterial disease (PAD) and proliferative diabetic retinopathy (PDR) in type 2 diabetes (T2D). Here, we explored the relationship between sight-threatening PDR and PAD. We screened for diabetic retinopathy (DR) and PAD in hospitalized patients with T2D. Patients with a diabetic duration of more than 10 years, HbA1c ≥7.5%, eGFR ≥60 mL/min/1.73 m2 and with PDR or with no diabetic retinopathy (NDR) were eligible for this cross-sectional study. Severities of DR were graded by digital retinal photographs according to the Early Treatment Diabetic Retinopathy Study (ETDRS) scale. We assessed PAD by measuring Ankle Brachial Index (ABI), Toe Brachial Index (TBI) and Doppler ultrasound. Statistical analyses were performed using SPSS 17.0 software. Of the 1544 patients, 169 patients with extreme eye (57 PDR and 112 NDR) phenotypes met the inclusion criteria. Patients with PDR had a significantly higher proportion of low ABI (≤0.99) and high ABI (≥1.3) than patients with NDR (28.1% and 15.8% vs. 14.3% and 6.2% respectively, P<0.05). PDR patients also had lower TBI than NDR patients (0.56±0.09 vs. 0.61±0.08, P<0.01). The proportion of patients with abnormal duplex ultrasound was higher in PDR than in NDR (21.1% vs. 9.8%, P<0.001). This showed that PDR associated with PAD could be defined in multiple ways: abnormal ABI (≤0.9) (OR = 3.61, 95% CI: 1.15-11.26), abnormal TBI (OR = 2.84, 95% CI: 1.19-6.64), abnormal duplex (OR = 3.28, 95% CI: 1.00-10.71), and critical limb ischemia (OR = 5.52, 95% CI: 2.14-14.26). Moreover, PDR was a stronger independent correlation factor for PAD than a diabetic duration of 10 years. In conclusion, PAD is more common in PDR than in NDR. It implies that PDR and PAD are mostly concomitant in T2D. We should focus on screening PAD in patients with PDR in clinical practice.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4379174PMC
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0122022PLOS

Publication Analysis

Top Keywords

diabetic retinopathy
20
lower extremity
8
extremity peripheral
8
type diabetes
8
proliferative diabetic
8
patients
7
diabetic
6
retinopathy
5
pdr
5
high prevalence
4

Similar Publications

This article reviews the critical issue of diabetic retinopathy (DR) in pregnant women with diabetes mellitus (DM), and describes the current understanding of the features of DM progression during pregnancy, as well as its pathogenic mechanisms, risk factors, and preventive measures for manifestation and progression of DR during gestation.

View Article and Find Full Text PDF

The introduction of faricimab, a drug targeting both vascular endothelial growth factor-A (VEGF-A) and angiopoietin-2, has enabled the implementation of the highly effective dual inhibition strategy in real clinical practice for patients with neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME), both previously treated with intravitreal injections and newly diagnosed. This article presents a series of 11 clinical cases involving patients with nAMD and DME who received loading doses of faricimab and continued ophthalmological observation. Among them, three patients with nAMD and two with DME were treatment-naïve, while the others were switched from alternative therapies to faricimab.

View Article and Find Full Text PDF

Unlabelled: Diabetic macular edema (DME) is a leading cause of visual impairment and blindness among diabetic patients, its prevalence is continuing to increase worldwide. Faricimab, a bispecific antibody, represents a new generation of treatments for DME.

Purpose: This study presents an indirect comparison of the effectiveness and safety of faricimab versus other treatment options for DME.

View Article and Find Full Text PDF

Purpose: To evaluate early response of retinal sensitivity (RS) and retinal morphology in diabetic macular edema (DME) patients after intravitreal anti-vascular endothelial growth factor (anti-VEGF) treatment.

Methods: Sixteen eyes of 12 DME patients were included in this study conducted prospectively. All eyes underwent functional and morphologic examination of the macular area using microperimetry and optical coherence tomography (OCT) before and after intravitreal anti-VEGF injection.

View Article and Find Full Text PDF

Association between sensitivity to thyroid hormone indices and type 2 diabetic microvascular complications in euthyroid patients.

Sci Rep

December 2024

Department of Endocrine and Metabolism, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, China.

The correlation between thyroid hormone (TH) sensitivity and microvascular complications of type 2 diabetes mellitus (T2DM) remains uncertain. This study aimed to explore the association between TH sensitivity and the risk of diabetic kidney disease (DKD), diabetic retinopathy (DR), and diabetic neuropathy (DNP) in euthyroid T2DM patients. This study included a total of 946 hospitalized T2DM patients and calculated their sensitivity to the TH index, and each patient completed screenings for DKD, DR, and DNP.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!